What is Apic Bio?
Apic Bio is at the forefront of developing first-in-class gene therapies targeting debilitating conditions such as SOD1 ALS, other genetic forms of ALS, and Alpha-1 Antitrypsin Deficiency. The company's proprietary THRIVE platform enables the discovery and advancement of treatments for various neurological indications. This strategic financing round is expected to fuel the continued development of its pipeline and expand its research into new therapeutic areas.
How much funding has Apic Bio raised?
Apic Bio has raised a total of $40M across 1 funding round:
Series A
$40M
Series A (2019): $40M with participation from The Alpha-1 Project, A1ATD Investors, Morningside Venture Investments, and ALS Investment Fund
Key Investors in Apic Bio
Morningside Venture Investments
Morningside Ventures is a venture capital firm with a history of making private equity and venture capital investments, often focusing on companies with strong entrepreneurial leadership and deep industry knowledge.
ALS Investment Fund
The ALS Investment Fund is a venture capital entity dedicated to investing in biotechnology companies that are developing treatments for neurodegenerative diseases, with a particular emphasis on ALS.
The Alpha-1 Project
The Alpha-1 Project is an organization focused on the pharmaceuticals sector, likely supporting initiatives and research related to Alpha-1 Antitrypsin Deficiency.
What's next for Apic Bio?
With this significant enterprise-level funding, Apic Bio is poised for accelerated growth and the advancement of its lead programs through clinical development. The company's focus on rare diseases and its innovative platform position it as a key player in the gene therapy space. Future endeavors will likely involve expanding its research initiatives and potentially forging strategic partnerships to bring its therapies to patients in need.
See full Apic Bio company page
